Clinical therapeutics · 2025
Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case Series.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Lili, Chen Jiaoyan, Yang Jurong, Sun Yan, Hou Mingyue, Wang Yunyan
Аннотация
PURPOSE: This is a series of reports describing how increasing the time interval between the administration of nafamostat mesylate (NM) and levocarnitine can suppress adverse reactions in maintenance hemodialysis patients after medication.
METHODS: Clinical assessments and medical record collection were conducted by nephrologists and nurses, while laboratory tests were performed by specialist doctors.
FINDINGS: Increasing the time interval between NM and levocarnitine administration (15-25 minutes) reduced adverse drug reactions, including nausea and vomiting, in 4 patients.
IMPLICATIONS: This may provide clinical doctors with new insights and research directions when using levocarnitine and NM for dialysis treatment.
METHODS: Clinical assessments and medical record collection were conducted by nephrologists and nurses, while laboratory tests were performed by specialist doctors.
FINDINGS: Increasing the time interval between NM and levocarnitine administration (15-25 minutes) reduced adverse drug reactions, including nausea and vomiting, in 4 patients.
IMPLICATIONS: This may provide clinical doctors with new insights and research directions when using levocarnitine and NM for dialysis treatment.